Journals / Solunum / 2016 / Cilt: 18 - Sayı: 2

Evaluating Fluoroquinolone Use in Patients Admitted to the Tuberculosis Outpatient Clinic

Journal
Solunum
Pages
111–115
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To avoid quinolone-resistant M. tuberculosis strains, further education is required.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Inelaborate use of new quinolones with strong anti-tuberculosis (TB) activity leads to difficulty in diagnosis and more importantly, quinolone-resistant Mycobacterium tuberculosis.
📊
Key Findings & Data:We aimed to determine the frequency of quinolone use in patients who were referred to our hospital for suspected TB and to evaluate the association between quinolone use and different clinical laboratory parameters.Methods: Between November 15 and December 15, 2013, all patients who were admitted to the TB outpatient clinic with no previous diagnosis of TB were included in this study.
💡
Conclusion & Impact:To avoid quinolone-resistant M. tuberculosis strains, further education is required.
🔬Design:Research Article
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Inelaborate use of new quinolones with strong anti-tuberculosis (TB) activity leads to difficulty in diagnosis and more importantly, quinolone-resistant Mycobacterium tuberculosis. We aimed to determine the frequency of quinolone use in patients who were referred to our hospital for suspected TB and to evaluate the association between quinolone use and different clinical laboratory parameters.Methods: Between November 15 and December 15, 2013, all patients who were admitted to the TB outpatient clinic with no previous diagnosis of TB were included in this study. Demographic and clinical laboratory findings and history of antibiotic use were recorded. Patients' quinolone use were questioned by showing fluoroquinolone antibiotic boxes' photographs available on the market. The departments of the doctors who prescribed quinolones were recorded.Results: The mean age of 179 patients included in the study was 37±16 (15-89) years. Among these, 113 patients (63.1%) were male. Seventy five patients (41.9%) were diagnosed as tuberculosis according to the clinical-radiological and/or bacteriological findings. Of 179 patients, 58.1% (n=104) had been prescribed antibiotics for current complaints before referral to our clinic. Sixteen patients (15%) had been recommended fluoroquinolones. Fluoroquinolones were prescribed by seven internal medicine specialists, five pulmonologists, three emergency medicine specialists, and one family medicine practitioner. Among 16 fluoroquinolones prescribed, nine were moxifloxacin, four were levofloxacin, and three were gemifloxacin. Quinolone use revealed a significant inverse relationship only with the presence of hemoptysis (p=0.04).Conclusion: Besides increased educational activities regarding the rational use of antibiotics in recent years, the quinolone group of antibiotics is still prescribed for suspected TB cases. To avoid quinolone-resistant M. tuberculosis strains, further education is required.

🔖

Cite This Article

İLİAZ, S., ÖNÜR, S. T., ORTAKÖYLÜ, M. G. (2016). Evaluating Fluoroquinolone Use in Patients Admitted to the Tuberculosis Outpatient Clinic. Solunum, Cilt: 18 - Sayı: 2, 111–115. https://ajindex.com/articles/314496

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. World Health Organization (WHO). Global Tuberculosis Report 2015. (Ac- cess date:07.03.2016) Available from: URL: http://www.who.int/tb/publi- cations/global_report/en/ Ruiz-Serrano MJ, Alcalá L, Martínez L, Díaz M, Marín M, González-Abad MJ, et al. In vitro activities of six fluoroquinolones against 250 clinical iso- lates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000
  2. [CrossRef] Gillespie SH. The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev 2016
  3. [CrossRef] Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al
  4. REMoxTB Consortium. Four-month moxifloxacin-based regi- mens for drug-sensitive tuberculosis. N Engl J Med 2014
  5. [CrossRef] Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalam- bous S, et al
  6. RIFAQUIN Trial Team. High-dose rifapentine with moxi- floxacin for pulmonary tuberculosis. N Engl J Med 2014
  7. [CrossRef] Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al
  8. OFLOTUB/Gatifloxacin for Tuberculosis Project. A four-month gatifloxa- cin-containing regimen for treating tuberculosis. N Engl J Med 2014
  9. [CrossRef] Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, et al. Empirical treat- ment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006
  10. [CrossRef] Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis 2005
  11. [CrossRef] Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004
  12. [CrossRef] Gosling RD. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003
  13. [CrossRef] Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009
  14. [CrossRef] Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM. Novel gyrase mutations in quinolone-resistant and hypersusceptible clinical isolates of Mycobacterium t